Argininosuccinic Aciduria (ASA)
A rare inherited urea cycle disorder caused by argininosuccinate lyase deficiency, leading to ammonia accumulation that can affect the brain and liver, managed with diet, medication, and close metabolic monitoring.
- Hyperammonemia emergency planning
- Dietary protein guidance
- Liver and neuro monitoring
- Estimated Prevalence
- ~1 in 70,000 births
- Typical Onset (Severe Form)
- First days of life
- Primary Gene
- ASL
- Key Treatment
- Ammonia Scavenger Therapy
Condition Overview
Argininosuccinic Aciduria (ASA) is a rare inherited disorder of the urea cycle, caused by deficiency of the enzyme argininosuccinate lyase (ASL). This enzyme is needed to break down argininosuccinate into arginine and urea, the body's main route for safely eliminating excess nitrogen. When ASL activity is reduced, ammonia and argininosuccinate accumulate, which can be toxic to the brain and other organs.
ASA can present in a severe neonatal form, often identified through newborn screening or after an infant becomes acutely unwell with poor feeding and lethargy, or in a milder, later-onset form. Beyond the immediate risk of hyperammonemic crisis, many patients with ASA also experience liver involvement and neurodevelopmental effects even when ammonia levels are controlled, distinguishing it somewhat from other urea cycle disorders.
Types and Subtypes
ASA severity is generally described by age of onset and degree of residual enzyme activity.
Symptoms and Signs
Symptoms relate both to acute ammonia toxicity and to chronic, ammonia-independent effects on the liver, hair, and nervous system.
Causes and Risk Factors
ASA is caused by inherited loss-of-function mutations in the ASL gene, with crisis episodes precipitated by specific physiological stressors.
Diagnosis and Investigations
Diagnosis combines biochemical evidence of urea cycle dysfunction with confirmatory enzymatic or genetic testing, often beginning with newborn screening.
Disease Severity and Risk Stratification
ASA severity is generally categorized by age of onset, residual enzyme activity, and degree of metabolic control achieved.
Standard Treatment Options
Lifelong management focuses on preventing ammonia accumulation through diet and medication, alongside monitoring for liver and developmental complications.
Advanced & Emerging Therapies
For patients with recurrent severe decompensation or significant liver involvement despite optimal medical management, further options exist.
Liver-Directed Therapy
Liver transplantation
Can correct the urea cycle defect and reduce or eliminate the risk of hyperammonemic crises in selected severe or refractory cases.
Investigational Gene-Based Approach
Gene therapy research
Early-stage research is exploring gene replacement and editing approaches for urea cycle disorders, including ASA.
Renal Replacement Therapy
Dialysis for severe acute hyperammonemia
Used emergently when ammonia levels are dangerously high and not responding adequately to medication alone.
Biomarkers & Precision Medicine
Biomarker monitoring in ASA tracks both acute ammonia risk and chronic, ammonia-independent organ effects.
When a Second Opinion May Be Important
Given the complexity of long-term urea cycle disorder management, specialist metabolic input is valuable at multiple stages.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in ASA depend heavily on the severity of the initial presentation, the promptness of treatment during hyperammonemic episodes, and long-term adherence to dietary and medical therapy.
Supportive Care and Living With ASA
Supportive care in ASA addresses nutrition, development, and family preparedness for metabolic emergencies.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families with Argininosuccinic Aciduria coordinate specialist review of metabolic test results and connect with centers experienced in long-term urea cycle disorder management, including liver transplant evaluation when appropriate.
Get a free case reviewFrequently Asked Questions
It is a rare inherited urea cycle disorder caused by deficiency of the enzyme argininosuccinate lyase, leading to ammonia accumulation in the body.
ASA is caused by mutations in the ASL gene that impair the urea cycle's ability to safely eliminate nitrogen waste.
Many cases are identified through newborn screening, while others present with severe lethargy and poor feeding in the first days of life or, in milder forms, later in childhood.
It is a dangerous buildup of ammonia in the blood that can affect the brain and requires urgent medical treatment.
Treatment includes a protein-restricted diet, ammonia scavenger medications, and arginine supplementation, with liver transplantation considered in select severe cases.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents must carry a mutated ASL gene copy.
No, many patients also experience liver enzyme elevation, brittle hair, hypertension, and learning difficulties even when ammonia is well controlled.
Diagnosis is supported by elevated plasma ammonia and argininosuccinate levels, confirmed with genetic testing of the ASL gene.
Some children with ASA experience developmental or learning difficulties, so early developmental assessment and support are recommended.
Yes. CancerFax can help you organize metabolic test results for specialist review, coordinate a second opinion, and connect you with centers experienced in long-term urea cycle disorder management and liver transplant evaluation.
Considering a Specialist Review for ASA?
Send your ammonia levels and genetic test results so a specialist can help refine your management plan.